drug
Jelmyto
Marketedupdated 4mo agoby $URGN UroGen Pharma Ltd.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- companyAll India Institute of Medical Sciences1 co-mentions · 1 sources
- companyAll India Institute of Medical Sciences Bathinda1 co-mentions · 1 sources
- tagOphthalmology1 co-mentions · 1 sources
- drugUGN-1031 co-mentions · 1 sources
- drugUGN-1041 co-mentions · 1 sources
- drugmitomycin1 co-mentions · 1 sources
- drugmitomycin SR1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 32 investigational indications.
all catalysts(1)
Trials studying Jelmyto
- phase3A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- phase3Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
- phase3A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
- phase2A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- phase3A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
- N/AAdaptive Radiation in Anal Cancer
- phase4Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer
- phase2Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 15, 2027
223 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Jan 20, 2031method-of-use (U-4256)US 100398324.4y
- Jan 20, 2031method-of-use (U-4172)US 122687454.4y
- Jan 20, 2031method-of-use (U-4256)US 124405684.4y
- Jan 20, 2031formulationUS 90400744.4y
- Jan 20, 2031formulationUS 90400744.4y
- Jan 20, 2031formulationUS 99500694.4y
- Jan 20, 2031formulationUS 99500694.4y
- May 21, 2029method-of-use (U-2095)US 96494282.7y
- Feb 1, 2029formulationUS 78062652.4y
- Jan 2, 2028compositionUS 95392411.3y
- Jul 19, 2026formulationUS 8186511
- Jul 19, 2026formulationUS 9205075
FDA exclusivities (2)
- Jun 12, 2028NPNP1.8y
- Apr 15, 2027ODE-289Orphan Drug (7y)223d
News(1)
- Preoperative Intravesical Mitomycin-C Before TURBT Cuts Recurrence Risk by 77% in NMIBC Over 5 YearsTwo doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.onclive · 3mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that